Doctors question evidence behind Pentagon plan for testosterone screening

Key Points:

• US Defense Secretary Pete Hegseth has mandated annual testosterone-deficiency screening for active-duty and reserve service members aged 30 and older, aiming to enhance military readiness, resilience, and performance.
• Medical experts express concern that widespread screening may lead to unnecessary or harmful testosterone treatments, including risks such as infertility, blood thickening, and mood changes, especially since natural testosterone decline varies and symptoms should guide treatment.
• The American Urological Association and Endocrine Society recommend testosterone therapy only for symptomatic individuals with confirmed deficiency, while some doctors argue that age 30 is too early for routine screening without solid evidence supporting its benefits.
• The policy is part of broader controversial health changes by Hegseth and Trump administration officials, including reversing flu vaccine mandates and altering vaccine advisory panels, prompting debate over scientific validity.
• Experts acknowledge potential benefits of appropriate testosterone testing to identify reversible causes of low testosterone, such as obesity, and note that broader screening might also provide insights into female soldiers' hormonal health, though detailed Pentagon guidelines remain unavailable.